Vistusertib
- Generic Name
- Vistusertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O3
- CAS Number
- 1009298-59-2
- Unique Ingredient Identifier
- 0BSC3P4H5X
- Background
Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
- Conditions
- Metastatic Malignant Solid NeoplasmRecurrent Lung Small Cell CarcinomaRecurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmStage IIIA Lung Small Cell Carcinoma AJCC v7Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7Stage IIIB Lung Small Cell Carcinoma AJCC v7Stage IV Lung Small Cell Carcinoma AJCC v7Unresectable Solid Neoplasm
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT03366103
- Locations
- πΊπΈ
Memorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
πΊπΈJohns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 531
- Registration Number
- NCT03334617
- Locations
- πͺπΈ
Research Site, Sevilla, Spain
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 25
- Registration Number
- NCT03205046
- Locations
- π¬π§
Research Site, Sutton, United Kingdom
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- π©π°
Rigshospitalet, Copenhagen, Denmark
π«π·Gustave Roussy, Villejuif, Val De Marne, France
π³π±Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- π¬π§
Royal Devon and Exeter Hospital, Exeter, United Kingdom
π¬π§University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
π¬π§Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT02546661
- Locations
- π¬π§
Research Site, Southampton, United Kingdom
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
- Conditions
- Progesterone Receptor NegativeStage III Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Triple-Negative Breast CarcinomaBRCA2 Mutation CarrierHigh Grade Ovarian Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaBRCA1 Mutation CarrierRecurrent Ovarian CarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 159
- Registration Number
- NCT02208375
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.